Publications

Conclusions: 

In a much larger sample, the incidence of NRG1 fusions across tumor types remained 0.2% (82/44,570). • There is notable variation within NRG1 fusions across tumors. The biologic and clinical significance of this heterogeneity is unclear. • Therapeutic studies should incorporate NRG1 fusion variants in any efficacy results.